Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The optimal treatment strategy for patients with clinical stage I (CS-1) seminoma is controversial. The objective of the current study was to evaluate the outcomes for patients considered to be at high risk of disease recurrence with a tumor size ≥6 cm. Patients were treated with either adjuvant radiotherapy (RT) or followed with surveillance.

METHODS: From the Danish Testicular Cancer database, the authors identified 473 patients with CS-1 seminoma with a tumor size ≥6 cm. Of these, 254 patients underwent adjuvant RT and 219 were followed with surveillance. Cumulative incidence function was applied to estimate the risk of disease recurrence, risk of second malignant neoplasm, and risk of receiving >1 line of treatment. Survival of the 2 groups was compared with the log-rank test and Cox model including age at diagnosis.

RESULTS: No significant differences were found with regard to overall survival or risk of a second malignant neoplasm. Patients undergoing adjuvant RT received more treatments per patient than patients followed with surveillance, but there was no significant difference noted with regard to the risk of receiving >1 line of treatment. The 10-year cumulative incidence of disease recurrence was 32% versus 2.8%, respectively, for patients followed with surveillance and adjuvant RT. In patients followed with surveillance who developed disease recurrence, there was a high incidence of second recurrences after RT.

CONCLUSIONS: The 10-year overall survival was found to be similar irrespective of primary treatment. Adjuvant RT was found to effectively reduce the rate of disease recurrence but resulted in the overtreatment of approximately two-thirds of the patients. The high incidence of second disease recurrences after RT in the patients followed with surveillance needs be addressed in future studies. Cancer 2017;123:1212-1218. © 2016 American Cancer Society.

Original languageEnglish
JournalCancer
Volume123
Issue number7
Pages (from-to)1212-1218
Number of pages7
ISSN0008-543X
DOIs
Publication statusPublished - 1 Apr 2017

    Research areas

  • Adolescent, Adult, Child, Denmark, Follow-Up Studies, Humans, Male, Neoplasm Staging, Population Surveillance, Radiotherapy, Adjuvant, Risk Factors, Seminoma, Treatment Outcome, Tumor Burden, Young Adult, Journal Article

ID: 52036871